InvestorsHub Logo
Followers 9
Posts 442
Boards Moderated 0
Alias Born 01/20/2014

Re: None

Wednesday, 03/12/2014 12:09:27 AM

Wednesday, March 12, 2014 12:09:27 AM

Post# of 404597
Anyone still interested: YouTube Audio file Elite Conference Call 18-Feb-2014:


"This is our year"


ELI-200: Undisclosed Abuse Deterrent opioid (most likely is Morphine/Naltrexone better EMBEDA). BE study done and good result. Even though this was second BE study but will be first NDA to be filed with FDA in 2014. I believe EMBEDA has once-daily and twice-daily, that's why Hakim pushing this first, we will have two version ELI-200 Mor/Nal once-daily and twice-daily. My opinion!

ELI-201: Oxycodone/Naltrexone twice-daily with ART/ADT. BE Study done and good result. Will be filed NDA with FDA in 2014. Three different twice daily formulations developed by Elite were tested in the study. This is generic of OxyContin.

ELI-216: Oxycodone/Naltrexone once-daily with ART/ADT.

ELI-154: Oxycodone once-daily ER with no ART/ADT , scale up at Elite for a $ 400 million dollar market in Europe.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News